![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 60.50 | 60.00 | 61.00 | 60.50 | 60.50 | 60.50 | 14,770 | 07:44:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -2.77 | 8.07M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/9/2019 01:24 | Interesting article - no direct connection to TexRAD. | ![]() lr2 | |
24/9/2019 20:27 | I'm expecting way better than this! | ![]() hazl | |
24/9/2019 19:26 | Obviously hazl's stop loss has not triggered yet. | ![]() ducatiman | |
24/9/2019 17:19 | Perhaps it's the bb that needs a spark not the company? 8-) Well done on such a creative idea Feedback! Bleepa has such potential and I would love to hear more discussion on various uses and not confine us to the NHS. | ![]() hazl | |
24/9/2019 15:59 | Down again and by the same margin as yesterday, will this keep dropping or will the management come out with a RNS which will give the share price the spark it so desperately needs! | sonie01 | |
24/9/2019 09:07 | Data can be tool for a forming an equal relationship between patients and the NHS Today 09:07 | ![]() newtothisgame3 | |
23/9/2019 14:29 | Eazzzy Thee Tiger !! God, Did you not go to accounting school ! When I majored @ hxxps://fisher.osu.e First thing we learnt was Cash Flow Positive and where to score Weed Agree 100% Balaji,Mike Hayball & Stephen Brown deserve every penny , Its the other parasites that need booting This Bleepa stunt ( still needs POC ) is the last throw of the Dice | ![]() botak54 | |
23/9/2019 14:25 | I'm a CFP. A certified financial planner But I doubt it was intended as that | ![]() davydoo | |
23/9/2019 14:14 | Ged, CFP had me puzzled too. I'm guessing it might mean Chief Financial Planner but I might be wrong. Knowing Bo it might just as easily mean C'mon u Fricking Plonkers. | ![]() lr2 | |
23/9/2019 14:07 | Bleepa @BleepaMe 6m6 minutes ago More "New innovations should be welcomed, championed and encouraged but they should only be adopted if they serve a purpose" Bleepa has been created to address a specific issue: how to securely share and discuss medical images instantly within clinical teams | ![]() newtothisgame3 | |
23/9/2019 13:52 | should we be giving a round of applause to those who got £2m invested at 1.2p? Anyone who felt hard done by can now buy for less | ![]() davydoo | |
23/9/2019 13:18 | Not much point in getting FDA approval for Texrad if they can't get anyone to buy it in Europe where it has the CE mark. | ![]() ducatiman | |
23/9/2019 13:08 | Ged, I'm not sure it was for FDA approval but rather the initial consultant fees to start the ball rolling. I still continue to believe the vast percentage was used to fund Bleepa. It's quite sad to see the price so far below the placing level of 1.2p and with not much appetite for investors to snap them up 10% below but these things can change with the drop of a hat. I'm hoping the bod don't let us down this time round. | petekand | |
23/9/2019 12:16 | YES GED agree we need news on Bleepa but they can't do everything at once. | ![]() hazl | |
23/9/2019 12:16 | talking to yourself again. | ![]() hazl | |
23/9/2019 12:11 | Well Done LR2 Reality posting,Informative and objective | ![]() botak54 | |
23/9/2019 12:07 | You really are an annoying little midge, Hazl. Keep up your positive prattle (at least until you disappear one day). In the meantime I'll continue discussing the real information offline. | ![]() lr2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions